NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis $1.20 +0.08 (+6.64%) As of 01:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADC Therapeutics Stock (NYSE:ADCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADC Therapeutics alerts:Sign Up Key Stats Today's Range$1.11▼$1.2250-Day Range$0.96▼$1.3652-Week Range$0.78▼$4.98Volume661,871 shsAverage Volume1.34 million shsMarket Capitalization$153.84 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC technology is designed to use antibodies to selectively deliver potent cytotoxic agents to cancer cells, with the goal of limiting exposure to healthy tissue. The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed at the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. ADC Therapeutics is also advancing a pipeline of investigational ADC candidates for hematologic malignancies and solid tumors. ADC Therapeutics was founded in 2011 and is headquartered in Lausanne, Switzerland, with operations and commercial activities supporting its oncology programs in the United States and other markets. The company’s research and development efforts are focused on expanding its ADC platform and developing additional targeted cancer therapies.AI Generated. May Contain Errors. Read More ADC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreADCT MarketRank™: ADC Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 314th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialADC Therapeutics has a consensus price target of $5.00, representing about 311.5% upside from its current price of $1.22.Amount of Analyst CoverageADC Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about ADC Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ADC Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.45% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 3.85, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADC Therapeutics has recently decreased by 14.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. News and Social Media1.5 / 5News SentimentN/A News SentimentADC Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.10% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADCT Stock News HeadlinesADC Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | prnewswire.comADC Therapeutics (ADCT) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 5 at 1:00 AM | Investors Alley (Ad)ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta OutlookAugust 16, 2026 | finance.yahoo.comADC Therapeutics SA (ADCT) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...August 14, 2026 | finance.yahoo.comADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdatesAugust 13, 2026 | prnewswire.comADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026August 6, 2026 | prnewswire.comSee More Headlines ADCT Stock Analysis - Frequently Asked Questions How have ADCT shares performed this year? ADC Therapeutics' stock was trading at $3.54 at the beginning of the year. Since then, ADCT shares have decreased by 65.7% and is now trading at $1.2150. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) issued its earnings results on Thursday, August, 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.11. The firm had revenue of $19.25 million for the quarter, compared to analysts' expectations of $18.89 million. Read the conference call transcript. When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $208 million in an IPO on Friday, May 15th 2020. The company issued 12,245,631 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/13/2026Today10/05/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ADCT's financial health is in the Red zone, according to TradeSmith. ADCT has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ADCT CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees191Year Founded2010Price Target and Rating Average Price Target for ADC Therapeutics$5.00 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+311.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.62 million Net Margins-121.77% Pretax Margin-122.28% Return on EquityN/A Return on Assets-32.74% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio2.97 Sales & Book Value Annual Sales$81.36 million Price / Sales1.91 Cash FlowN/A Price / Cash FlowN/A Book Value($1.50) per share Price / Book-0.81Miscellaneous Outstanding Shares127,670,000Free Float121,157,000Market Cap$155.12 million OptionableOptionable Beta1.86 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSE:ADCT) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
